COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
COSCIENS Biopharma Inc. (CSCI)
Company Research
Source: GlobeNewswire
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today reported its financial and operating results for the quarter ended June 30, 2024 and provided a corporate update. “We are very pleased with the ongoing post-merger integration process and expect to be providing a fulsome update shortly. The newly combined management team is currently completing our detailed work to identify synergies and cost reduction opportunities as we review and prioritize our now combined portfolio of programs and products. In that review, our goal
Show less
Read more
Impact Snapshot
Event Time:
CSCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSCI alerts
High impacting COSCIENS Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
CSCI
News
- COSCIENS Biopharma Announces Change to Board of DirectorsGlobeNewswire
- COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Yahoo! Finance]Yahoo! Finance
- COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Financial Post (Toronto, Ontario, Canada)]Financial Post
- COSCIENS Biopharma Announces Appointment of Pierre Labbé as DirectorGlobeNewswire
- COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs [Financial Post (Toronto, Ontario, Canada)]Financial Post
CSCI
Sec Filings
- 10/8/24 - Form 6-K
- 10/1/24 - Form 6-K
- 9/23/24 - Form 6-K
- CSCI's page on the SEC website